Effect of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamideantiviral Therapy on Renal Function in Chronic Hepatitis B Patients: A Real-World Retrospective Study

Methods: This retrospective observational cohort study investigated factors related to renal function in 154 patients with NUC-experienced CHB who received ETV, TDF, and TAF therapy for 48 weeks. Changes in UREA, uric acid (UA), creatinine (Cr), and estimated glomerular filtration rate (eGFR) were analyzed using a one-way analysis of variance. A linear mixed-effects model for repeated measures was used to evaluate the correlation between baseline information and eGFR changes 48 weeks following treatment initiation. The model considered sex, baseline age, viral load, aminotransferases, renal function, and treatment group as fixed effects, and incorporated random effects for individual subjects.

Results: There were no significant differences in UA or Cr levels during therapy over time. The eGFR level was elevated in ETV-treated patients (117.5 ± 16.65 mL/min/1.7m vs 109.8 ± 15.69 mL/min/1.7m, =0.027), whereas it did not change significantly in TDF- (123.6 ± 28.54 mL/min/1.7m vs 115.5 ± 20.44 mL/min/1.7m, =0.070) and TAF-treated (121.6 ± 23.44 mL/min/1.7m vs 113.4 ± 16.90 mL/min/1.7m, =0.053) patients. Younger patients (<30 years) and those with higher HBV DNA (> 7 logIU/mL) and lower alanine aminotransferase levels (<5 × upper limit of normal) showed a significant improvement in eGFR elevation during NUCs therapy. The linear mixed-effects model showed that the baseline HBV DNA level was an important positive predictor of eGFR elevation at 48 weeks following treatment initiation (estimate was 1.437 and 2.449, <0.001).

Conclusion: In real-life experience, ETV, TDF, and TAF therapy may not be associated with eGFR changes in NUC-experienced CHB patients without baseline renal impairment.

References

Rodriguez-Novoa S, Garcia-Samaniego J, Prieto M, Calleja J, Pascasio J, Delgado Blanco M . Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study. J Clin Gastroenterol. 2016; 50(9):779-89. DOI: 10.1097/MCG.0000000000000569. View

Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M . Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. Hepatol Res. 2019; 49(11):1294-1304. DOI: 10.1111/hepr.13399. View

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I . Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2012; 381(9865):468-75. DOI: 10.1016/S0140-6736(12)61425-1. View

Yapali S, Lok A . Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects. Gastroenterology. 2013; 146(1):15-9. DOI: 10.1053/j.gastro.2013.11.028. View

Stasi C, Silvestri C, Voller F . Hepatitis B vaccination and immunotherapies: an update. Clin Exp Vaccine Res. 2020; 9(1):1-7. PMC: 7024731. DOI: 10.7774/cevr.2020.9.1.1. View

Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P . Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011; 55(6):1235-40. DOI: 10.1016/j.jhep.2011.03.030. View

. [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2020; 27(12):938-961. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.007. View

Liu J, Liang W, Jing W, Liu M . Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019; 97(3):230-238. PMC: 6453311. DOI: 10.2471/BLT.18.219469. View

10.

Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M . Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis. 2021; 21(1):567. PMC: 8201741. DOI: 10.1186/s12879-021-06237-x. View

11.

Gane E, Deray G, Liaw Y, Lim S, Lai C, Rasenack J . Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2013; 146(1):138-146.e5. DOI: 10.1053/j.gastro.2013.09.031. View

12.

Lee J, Lee J, Hwang S, Lee K, Kim J, Ryu J . Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study. Hepatol Int. 2022; 16(3):537-544. DOI: 10.1007/s12072-022-10320-z. View

13.

Jeong S, Shin H, Kim H . Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Intervirology. 2021; 65(2):94-103. PMC: 9153351. DOI: 10.1159/000519440. View

14.

Jaryal A, Kumar V, Sharma V . Renal disease in patients infected with hepatitis B virus. Trop Gastroenterol. 2016; 36(4):220-8. DOI: 10.7869/tg.295. View

15.

Turner D, Drak D, OConnor C, Templeton D, Gracey D . Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service. AIDS Res Ther. 2019; 16(1):40. PMC: 6898922. DOI: 10.1186/s12981-019-0256-9. View

16.

Vu V, Trinh S, Le A, Johnson T, Hoang J, Jeong D . Hepatitis B and renal function: A matched study comparing non-hepatitis B, untreated, treated and cirrhotic hepatitis patients. Liver Int. 2018; 39(4):655-666. DOI: 10.1111/liv.14009. View

17.

Chan H, Shaikh J, Gupta S, Hamed K . Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis. Adv Ther. 2016; 33(5):862-75. PMC: 4882346. DOI: 10.1007/s12325-016-0337-2. View

18.

Mak L, Hoang J, Won Jun D, Chen C, Peng C, Yeh M . Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatol Int. 2021; 16(1):48-58. DOI: 10.1007/s12072-021-10271-x. View

19.

Zhang L, Zuo L, Xu G, Wang F, Wang M, Wang S . Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant. 2007; 22(4):1093-9. DOI: 10.1093/ndt/gfl763. View

20.

Appel G . Viral infections and the kidney: HIV, hepatitis B, and hepatitis C. Cleve Clin J Med. 2007; 74(5):353-60. DOI: 10.3949/ccjm.74.5.353. View